Low skeletal muscle radiodensity predicts response to CDK4/6 inhibitors plus aromatase inhibitors in advanced breast cancer

In a retrospective study, researchers investigated the association between skeletal muscle radiodensity (SMD) and therapeutic responses in patients with advanced HR+ HER2- breast cancer. Data from 247 patients showed that low SMD predicted poor treatment outcomes among patients undergoing first-line treatment with aromatase inhibitors and CDK4/6 inhibitors.